Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2026 · 10-Q
Revenue$201.66M$201.66M+11.2% vs Q2 2025 Net Income$2.24M$2.24MN/M vs Q2 2025 EPS Diluted$0.02$0.02N/M vs Q2 2025 Gross Profit$91,878,000+18.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$19,959,000−1.8% Free Cash Flowderived$11,740,000−16.2% Margins · derivedGross margin45.6%+3.0 pt vs Q2 2025
Operating margin-4.8%+21.4 pt vs Q2 2025
Net margin1.1%+26.0 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 28, 2026 · 28 d after period end